ClinicalTrials.gg
RecruitingNCT07369557Updated Oct 6, 2026

Mindfulness Training During Accelerated TMS for Depression

An interventional study of Guided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app in Depression, sponsored by Medical University of South Carolina. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Depression by Medical University of South Carolina — 17 open to participants now, 21 under way, none of them phase 3. Depression · Medical University of South Carolina.

Planned enrollment
35th of 45
20 · median 46
Started
2026
with 5 others
No phase
31 of 47
13 open now
Primary completion
2026-12
later than 3 of 20 live
Registered
44th of 47
by date

Among the 47 studies in Depression by Medical University of South Carolina, this one is the 35th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2026, is one of 31 with no phase, reaches primary completion later than 3 of the 20 other live ones, and was the 44th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

17 of the 47 studies in Depression by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Depression by Medical University of South Carolina, or all of them as a file.
02

Study summary

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

03

Conditions studied

  • Depression

Keywords

  • Major Depressive Disorder
  • Transcranial Magnetic Stimulation
  • Theta-Burst Stimulation
  • Mindfulness
  • Positive Affect
  • Hedonic Tone
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of MDD and eligible for aiTBS at MUSC
  • Already enrolled in aiTBS course at MUSC
  • English proficiency
  • Smartphone or willingness to use study-provided device

Exclusion criteria

Exclusion Criteria:

  • TMS (e.g., seizure history, implants, pregnancy)
  • Concurrent neuromodulation (ECT, VNS)
  • Psychotic disorder, bipolar disorder, active substance use disorder, high suicide risk
  • Unable/unwilling to engage in mindfulness or complete questionnaires
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Mindfulness Training during aiTBS

    Behavioral: Guided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app

Interventions

  • BehavioralGuided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app

    5-15 minutes of mindfulness exercises during aiTBS inter-session intervals (9 total per day) for five consecutive treatment days; optional additional practices allowed. App analytics (with permission) and self-reports quantify engagement.

06

What researchers measure

Primary outcomes

  1. Feasibility of Guided Mindfulness Practice During aiTBS (Adherence Rate)

    Proportion of participants who complete all mandatory guided practice on each of the five aiTBS treatment days. Calculated as: number completing all five days ÷ total enrolled. Higher values indicate better feasibility.

    Time frame: Day 0 to Day 5

  2. Tolerability of Guided Mindfulness Practice During aiTBS (Adverse Events)

    Number and severity of meditation-related adverse events recorded via participant report and study staff observation. Higher values indicate worse tolerability.

    Time frame: Day 0 to Day 5

Secondary outcomes

  1. Change in State Mindfulness (Toronto Mindfulness Scale Total Score)

    Change in Toronto Mindfulness Scale (TMS) total score from baseline to Day 5. Higher scores indicate greater state mindfulness.

    Time frame: Day 0 to Day 5

  2. Change in Hedonic Tone (Snaith-Hamilton Pleasure Scale Total Score)

    Change in Snaith-Hamilton Pleasure Scale (SHAPS) total score from baseline to Day 5. Lower scores indicate improved hedonic tone.

    Time frame: Day 0 to Day 5

  3. Change in Perceived Ease of Meditation (0-10 Rating)

    Change in meditation ease rating on a 0-10 numeric scale (0 = not at all easy; 10 = extremely easy). Higher scores indicate greater perceived ease.

    Time frame: Day 0 to Day 5

  4. Change in Trait Mindfulness (CAMS-R Total Score)

    Change in Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) total score from baseline to Week 12. Higher scores indicate greater trait mindfulness.

    Time frame: Baseline to Week 12 (with Week-4 assessment)

  5. Durability of Antidepressant Response (Percent Change in PHQ-9)

    Percent change in PHQ-9 total score from baseline to Week 4. Lower scores indicate improvement

    Time frame: Baseline to Week 4

  6. Meditation Engagement (App Analytics and Self-Report)

    Engagement with the Waking Up app measured by total minutes practiced, number of Foundations completed, and cumulative meditation minutes. Higher values indicate greater engagement.

    Time frame: Day 0 to Week 12

07

Study locations

1 of 2 sites recruiting
  • IOP
    Charleston, South Carolina 29407, United States
    Recruiting
  • Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry
    Charleston, South Carolina 29407, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Informed consent form

Time frame: Within 12 months of study completion

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Oct 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 27, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Dec 30, 2026was Sep 2026
CompletionEst.
Apr 30, 2027was Oct 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Dec 30, 2026
Oct 6, 2026
Study completion
Oct 30, 2026→Apr 30, 2027
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 30, 2026→Dec 30, 2026
    Study completion Oct 30, 2026→Apr 30, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07369557
Responsible party
Clayton Olash (Medical/Dental Resident, Medical University of South Carolina) — Principal investigator
First posted
Jan 27, 2026
Start date
Apr 13, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Clayton Olash, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion